Actively Recruiting
Reducing High Risk Primary Tumor Clinical Target Volumes (CTVp1) in Non-metastatic Nasopharyngeal Carcinoma
Led by Zhongshan People's Hospital, Guangdong, China · Updated on 2023-08-16
454
Participants Needed
1
Research Sites
317 weeks
Total Duration
On this page
Sponsors
Z
Zhongshan People's Hospital, Guangdong, China
Lead Sponsor
S
Sun Yat-Sen University Cancer Center
Collaborating Sponsor
AI-Summary
What this Trial Is About
To evaluate the long-term local control, survival rate, acute and late radiation related toxicities, quality of life after reducing high risk primary tumor clinical target volumes (CTVp1) in non-metastatic nasopharyngeal carcinoma treated with IMRT.
CONDITIONS
Official Title
Reducing High Risk Primary Tumor Clinical Target Volumes (CTVp1) in Non-metastatic Nasopharyngeal Carcinoma
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Histologic confirmation of nonkeratinizing nasopharyngeal carcinoma (WHO II-III)
- Newly diagnosed stage I to IVa nasopharyngeal carcinoma
- Tumor confined to one side of the nasopharynx and not crossing the midline confirmed by nasopharyngoscope and MRI
- Planned to receive curative intensity-modulated radiotherapy (IMRT) with chemotherapy according to guidelines
- No previous cancer treatment
- Karnofsky performance status score of at least 70
- Age between 18 and 70 years
- Adequate blood, liver, and kidney function
- Provided written informed consent after being informed about the study
You will not qualify if you...
- Treatment given with palliative intent
- Previous radiotherapy, chemotherapy, or surgery to the nasopharynx (except diagnostic procedures)
- Disease progression after neoadjuvant chemotherapy in locally advanced nasopharyngeal carcinoma
- Presence of distant metastasis
- Keratinized squamous cell carcinoma or basal cell-like squamous cell carcinoma
- Prior malignancy except treated non-melanoma skin cancer, in situ cervical cancer, and papillary thyroid carcinoma
- New York Heart Association class 3 or 4 heart failure, unstable angina, recent myocardial infarction, or clinically significant arrhythmia requiring treatment
- Pregnancy or lactation
- Mental disorders, drug or alcohol addiction, or lack of full legal capacity to consent
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Zhongshan City People's Hospital
Zhongshan, Guangdong, China, 528403
Actively Recruiting
Research Team
G
Gui-qiong Xu
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
TRIPLE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here